At RESI Boston 2024, held on September 25th at the Westin Copley Place, Montgomery County-based biotechnology company miRecule, a client of BioHealth Innovation Inc. (BHI), showcased its groundbreaking RNA therapeutic programs. As part of Biotech Week Boston, RESI Boston provided a premier opportunity for miRecule to engage in in-person networking with potential investors and partners, followed by virtual partnering sessions on September 26-27. miRecule presented the innovative work stemming from its DREAmiR™ platform, which leverages genomic and patient outcome data to create highly personalized RNA therapies for cancer and muscular dystrophy.
miRecule highlighted its lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy at the event. Their DREAmiR™ platform, designed to target specific genetic abnormalities underlying these diseases, positions miRecule as a leader in precision medicine. The company’s ability to tailor RNA therapies based on patient data offers promising advancements for patients struggling with debilitating conditions, aiming to create a future where they can live free from the burden of their disorders.